ReviewZhongguo fei ai za zhi = Chinese journal of lung cancer2026
[Advances in Systemic Therapy for Extensive-stage Small Cell Lung Cancer in the Era of Precision Treatment].
Review in Zhongguo fei ai za zhi = Chinese journal of lung cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Extensive-stage small cell lung cancer (ES-SCLC) is characterized by rapid progression, a high risk of recurrence, and poor prognosis, and remains a major therapeutic challenge in lung cancer. In recent years, immune checkpoint inhibitors combined with Platinum-Etoposide chemotherapy have become the standard first-line treatment for ES-SCLC, driving a shift from conventional chemotherapy toward multimodal combination strategies and precision-guided patient stratification, while creating both new opportunities and challenges for further therapeutic improvement. Following the clinical treatment pathway, this review summarizes advances in multidisciplinary combination treatment for ES-SCLC, including chemotherapy, immunotherapy, targeted therapy, radiotherapy, and traditional Chinese medicine, with emphasis on standard regimens, maintenance therapy, clinical limitations, and emerging research directions. This review aimed to provide a reference for individualized treatment and comprehensive disease management of ES-SCLC in the era of precision medicine. .
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.